Genenta Expands Cell Therapy Production with AGC Biologics

Genenta Science (NASDAQ: GNTA), a trailblazer in immuno-oncology and cell-based treatments, has deepened its collaboration with AGC Biologics, a global contract development and manufacturing organization (CDMO). The enhanced partnership includes a dedicated GMP manufacturing suite at AGC Biologics’ Cell and Gene Center of Excellence in Milan, exclusively for producing Genenta’s innovative cell therapy, Temferon. This move ensures high-quality production standards and better supports Genenta’s growing clinical programs.

Driving Progress in Cancer Trials

As part of its clinical advancements, Genenta has already begun its Phase 1/2a trial for metastatic renal cell cancer (mRCC), launched in late 2024. Six patients are expected to be treated by mid-2025. Alongside this, the company is continuing its important work on glioblastoma multiforme (GBM). In total, Genenta plans to produce 27 personalized drug products in 2025, signaling a significant step toward delivering innovative cancer therapies to more patients.

“This expanded partnership with AGC Biologics is a crucial step in fulfilling our commitment to patients participating in our GBM and mRCC trials,” said Pierluigi Paracchi, CEO and Co-founder of Genenta. “By increasing our manufacturing capacity, we’re better positioned to advance our mission of transforming cancer care through cutting-edge cell-based therapies.”

Temferon: A Promising Approach to Solid Tumors

Temferon, Genenta’s groundbreaking therapy, is designed to change the way tumors interact with the immune system. It works by reprogramming the tumor’s environment, reducing immune suppression, and boosting T-cell responses.

“Our research shows Temferon has the potential not only as a standalone treatment but also in combination with other immunotherapies like checkpoint inhibitors and CAR-T cells,” explained Prof. Luigi Naldini, Co-founder of Genenta. “This approach brings us closer to offering new, effective treatment options for solid tumors.”

Showcasing Innovation During JPM Healthcare Week

Genenta will share its progress and technology during Biotech Showcase 2025 in San Francisco from January 13–15. CEO Pierluigi Paracchi will also speak at "Italy on the Move", an event organized by Italy’s Ministry of Foreign Affairs, on January 15 at the INNOVIT Italian Innovation and Culture Hub. The event will feature industry leaders like Karthic Jayaraman, Partner at TPG Capital, and Frederick Beddingfield, CEO of Rubedo Life Sciences.

By expanding its manufacturing capabilities and continuing its commitment to groundbreaking research, Genenta is advancing toward its vision of providing life-changing therapies for patients battling difficult-to-treat cancers.